The Role of Bortezomib, Thalidomide and Lenalidomide in the Management of Multiple Myeloma
详细信息 查看全文
- 作者：Dr Andrea Messori (1)
Dario Maratea (1)
Chiara Nozzoli (2)
Alberto Bosi (2) - 刊名：PharmacoEconomics
- 出版年：2011
- 出版时间：April 2011
- 年：2011
- 卷：29
- 期：4
- 页码：269-285
- 全文大小：183KB
- 参考文献：1. Raab MS, Podar K, Breitkreutz I, et al. Multiple myeloma. Lancet 2009 Jul 25; 374 (9686): 324鈥?9 CrossRef
2. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564鈥? CrossRef
3. Inamoto Y, Kurahashi S, Imahashi N, et al. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation. Am J Hematol 2009 May; 84 (5): 283鈥? CrossRef
4. Avet-Loiseau H, Soulier J, Fermand JP, et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia 2010 Mar; 24 (3): 623鈥? CrossRef
5. Kapoor P, Kumar S, Fonseca R, et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009 Jul 16; 114 (3): 518鈥?1 CrossRef
6. Chen YI, Chang YM. Covariates-dependent confidence intervals for the difference or ratio of two median survival times. Stat Med 2007 May 10; 26 (10): 2203鈥?3 CrossRef
7. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431鈥? CrossRef
8. Rajkumar SV, Rosinol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008; 26: 2171鈥? CrossRef
9. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008; 93: 124鈥? CrossRef
10. Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009; 27 (11): 1788鈥?3 CrossRef
11. Lokhorst HM, van der Holt B, Zweegman S, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010 Feb 11; 115 (6): 1113鈥?0 CrossRef
12. Zervas K, Mihou D, Katodritou E, et al. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group. Ann Oncol 2007; 18: 1369鈥?5 CrossRef
13. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021鈥?0 CrossRef
14. Gelber RD, Goldhirsch A, Cole BF. Evaluation of effectiveness: Q-TWiST. The International Breast Cancer Study Group. Cancer Treat Rev 1993; 19 Suppl. A: 73鈥?4
15. Marcus R, Aultman R, Jost F. A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin鈥檚 lymphoma. Br J Cancer 2010 Jan 5; 102 (1): 19鈥?2 CrossRef
16. Jang RW, Le Ma卯tre A, Ding K, et al. Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 Trial. J Clin Oncol 2009 Sep 10; 27 (26): 4268鈥?3 CrossRef
17. Saad AA, Sharma M, Higa GM. Treatment of multiple myeloma in the targeted therapy era. Ann Pharmacother 2009 Feb; 43 (2): 329鈥?8
18. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414鈥?3 CrossRef
19. Hussein MA. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost 2006; 95: 924鈥?0
20. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009 Aug 12; 2: 36 CrossRef
21. Rajkumar SV, Jacobus S, Callander NS, et al., Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial [published erratum appears in Lancet Oncol 2010 Jan; 11 (1): 14]. Lancet Oncol 2010 Jan; 11 (1): 29鈥?7
22. Zonder JA, Crowley J, Hussein MA, et al. Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232 [abstract 77]. The American Society of Hematology 49th Annual Meeting; 2007 Dec 8-11; Atlanta (GA). Blood (AHS Annual Meeting Abstracts) 2007; 110 (11): 77
23. Harousseau JL, Moreau P. Evolving role of stem cell transplantation in multiple myeloma. Clin Lymphoma Myeloma 2005 Sep; 6 (2): 89鈥?5 CrossRef
24. Bahlis NJ, Mansoor A, Lategan JC, et al. Lenalidomide overcomes poor prognosis conferred by deletion of chromosome 13 and t(4;14)in multiple myeloma: MM016 trial [abstract 3557]. The American Society of Hematology 49th Annual Meeting; 2006 Dec 9-12; Orlando (FL). Blood (ASH Annual Meeting Abstracts) 2006; 108 (11): 3557
25. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565鈥?1 CrossRef
26. Harousseau JL, Mathiot C, Attal M, et al. VELCADE/dexamethasone (vel/D) versus VAD as induction treatment prior to autologous stem cell transplantion (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 trial [abstract 450]. The American Society of Hematology 49th Annual Meeting; 2007 Dec 8-11; Atlanta (GA). Blood (ASH Annual Meeting Abstracts) 2007; 110: 450
27. Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiplemyeloma: results of an IFM phase II study. Haematologica 2006; 91: 1498鈥?05
28. Curran MP, McKeage K. Bortezomib: a review of its use in patients with multiple myeloma. Drugs 2009; 69 (7): 859鈥?8 CrossRef
29. Cavo M, Patriarca F, Tacchetti P, et al. Bortezomib (velcade庐)-thalidomide-dexamethasone (VTD) vs thalidomidedexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM) [abstract 73]. The American Society of Hematology 49th Annual Meeting; 2007 Dec 8-11; Atlanta (GA). Blood (ASH Annual Meeting Abstracts) 2007; 110: 73
30. Palumbo A, Gay F, Falco P, et al. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients [published erratum appears in J Clin Oncol 2010 May 1; 28 (13): 2314]. J Clin Oncol 2010 Feb 10; 28 (5): 800鈥? CrossRef
31. Myeloma Trialists鈥?Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001; 113: 1020鈥?4 CrossRef
32. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289鈥?4 CrossRef
33. Palumbo A, Sezer O, Kyle R, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stemcell transplantation. Leukemia 2009; 23 (10): 1716鈥?0 CrossRef
34. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825鈥?1 CrossRef
35. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 370: 1209鈥?8 CrossRef
36. Wijermans P, Schaafsma M, Termorshuizen F, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 study. J Clin Oncol 2010 Jul 1; 28 (19): 3160鈥? CrossRef
37. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009 Aug 1; 27 (22): 3664鈥?0 CrossRef
38. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA鈥揑talian Multiple Myeloma Network. J Clin Oncol 2007; 25: 4459鈥?5 CrossRef
39. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906鈥?7 CrossRef
40. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010 May 1; 28 (13): 2259鈥?6 CrossRef
41. San Miguel J, Harousseau JL, Joshua D, et al. Individualizing treatment of patients with myeloma in the era of novel drugs. J Clin Oncol 2008; 26 (16): 2761鈥? CrossRef
42. Richardson PG, Mitsiades C, Schlossman R, et al. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther 2008 Jul; 8 (7): 1053鈥?2 CrossRef
43. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005 Jun; 129 (6): 755鈥?2 CrossRef
44. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986; 105: 8鈥?1
45. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating drugs. N Engl J Med 1984; 310: 1353鈥? CrossRef
46. Giles FJ, Wickham NR, Rapoport BL, et al. Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol. Am J Hematol 2000; 63: 125鈥?0 CrossRef
47. Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003; 21: 2732鈥? CrossRef
48. MacLennan IC, Chapman C, Dunn J, et al. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. Lancet 1992; 339: 200鈥?
49. Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006; 132: 584鈥?3 CrossRef
50. Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001; 12: 991鈥? CrossRef
51. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458鈥?4 CrossRef
52. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133鈥?2 CrossRef
53. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123鈥?2 CrossRef
54. Harousseau JL, Dimopoulos MA, Wang M, et al. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 2010 Oct; 95 (10): 1738鈥?4 CrossRef
55. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487鈥?8 CrossRef
56. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110: 3557鈥?0 CrossRef
57. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25: 3892鈥?01 CrossRef
58. von Lilienfeld-Toal M, Hahn-Ast C, Furkert K, et al. A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. Eur J Haematol 2008 Oct; 81 (4): 247鈥?2 CrossRef
59. Dimopoulos MA, Hamilos G, Zomas A, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J 2004; 5: 112鈥? CrossRef
60. Offidani M, Corvatta L, Piersantelli MN, et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiplemyeloma. Blood 2006 Oct 1; 108 (7): 2159鈥?4 CrossRef
61. Offidani M, Corvatta L, Polloni C, et al. Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study. Br J Haematol 2009 Mar; 144 (5): 653鈥? CrossRef
62. Anderson KC, Jagannath S, Jakubowiak A, et al. Phase II study of lenalidomide (len), bortezomib (bz), and dexamethasone (dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM) [abstract no. 8545]. Proc Am Soc Clin Oncol 2008; 26: 8545
63. Palumbo A, Larocca A, Falco P, et al. Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. Leukemia 2010 May; 24 (5): 1037鈥?2 CrossRef
64. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111 (5): 2516鈥?0 CrossRef
65. Sistema Farmadati (aggiornamento dicembre 2010), Piacenza, Italia [online; subscriber only]. Available from URL: http://www.farmadati.it [Accessed 2011 Jan 15]
66. Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009 Nov; 23 (11): 2147鈥?2 CrossRef
67. Armoiry X, Fagnani F, Benboubker L, et al. Estimating direct costs of care for patients with relapsed or refractory multiple myeloma in French hospitals [abstract no. 8596]. J Clin Oncol 2008; 26 (15S): 8596
68. Hornberger J, Rickert J, Dhawan R, et al. Comparisons of regimen costs of bortezomib and lenalidomide for treatment of advanced, relapsed multiple myeloma [abstract no.1229]. Haematologica 2008 Jun; 93 (Suppl. 1): 477
69. Yoong K, Attard C, Jivraj F, et al. Cost effectiveness analysis of bortezomib in previously untreated multiple myeloma patients in Canada [abstract no. PCN81]. 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2009 Oct 24-27; Paris
70. Liwing J, Gjonnes L, Sandberg I, et al. The cost-effectiveness of bortezomib for relapsed/ refractory multiple myeloma: a nordic comparison [abstract no. PCN86]. 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2009 Oct 24-27; Paris
71. Joseph I, Facon T, Lewis P, et al. Cost-effectiveness of thalidomide combined with melphalan and prednisone in previously untreated multiple myeloma in Wales [abstract no PCN 75]. 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2009 Oct 24-27; Paris
72. De Abreu LR, Colman S, Lee C. Thalidomide plus melphalan and prednisone for Australian patients newly diagnosed with multiple myeloma is cost-effective when compared with melphalan and prednisone alone [abstract no. PSY32]. 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2009 Oct 24-27; Paris
73. Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998 Oct; 13 (10): 716鈥? CrossRef
74. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006 Mar 25; 332 (7543): 699鈥?03 CrossRef
75. Detsky AS, Laupacis A. Relevance of cost-effectiveness analysis to clinicians and policy makers. JAMA 2007; 298: 221鈥? CrossRef
76. Ferner RE, Hughes DA, Aronson JK. NICE and new: appraising innovation. BMJ 2010; 340: b549 CrossRef
77. Christie S. Lifesaving myths. Health Serv J 2009 Jun 25; 119 (6162): 14
78. Gajraj E, Chung H, Boysen M, et al. Lenalidomide for the treatment of relapsed multiple myeloma. Lancet Oncol 2009 Jul; 10 (7): 647鈥? CrossRef
79. Low E. NICE: friend and foe. Nat Clin Pract Oncol 2007 Mar; 4 (3): 135 CrossRef
80. Goss TF, Szende A, Schaefer C, et al. Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States. Cancer Control 2006 Dec; 13 Suppl.: 17鈥?5
81. Fojo T, Grady C. How much is life worth: cetuximab, nonsmall cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009; 101 (15): 1044鈥? CrossRef
82. Messori A, Trippoli S. Drug-eluting stent for treatment of coronary artery disease: NICE technology appraisal guidance. Heart 2009; 95 (10): 847
83. Santarlasci B, Burchini G, Simbula S, et al. Progetto 芦Osservatorio sull鈥檌nnovazione禄: schede web sui prodotti innovativi comprensive di analisi economica semplificata. Giornale italiano di Farmacia clinica 2008; 22: 24鈥?0
84. National Institute for Health and Clinical Excellence. Bortezomib monotherapy for relapsed multiple myeloma. Technology appraisal guidance 129. London: NICE, 2007 [online]. Available from URL: http://www.nice.org.uk/TA129 [Accessed 2010 Jun 27]
85. National Institute for Health and Clinical Excellence. Lenalidomide for the treatment of multiplemyeloma in people who have received at least one prior therapy. Technology appraisal guidance 171. London: NICE, 2009 [online]. Available from URL: http://www.nice.org.uk/TA171 [Accessed 2010 Jun 27]
86. National Institute for Health and Clinical Excellence. Multiple myeloma (first line)鈥揵ortezomib and thalidomide. Final appraisal determination (26 August 2010) [online]. Available from URL: http://guidance.nice.org.uk/TA/Wave18/53 [Accessed 2010 Dec 23]
87. Garber AM, McClellan MB. Satisfaction guaranteed: 鈥榩ayment-by-results鈥?for biologic agents. N Engl J Med 2007; 357: 1575鈥? CrossRef
88. Messori A, Trippoli S, Bonacchi M, et al. Left ventricular assist device as destination therapy: application of the payment-by-results approach for the device reimbursement. J Thorac Cardiovasc Surg 2009; 138 (2): 480鈥? CrossRef
89. De Ambrosis P. Risk sharing e rimborso in base al risultato. Dialogo sui farmaci 2008; (5): 235鈥?
90. Messori A. MS risk sharing scheme: outcome based schemes are more common than you think. BMJ 2010 Jul 7; 341: c3588 CrossRef - 作者单位：Dr Andrea Messori (1)
Dario Maratea (1)
Chiara Nozzoli (2)
Alberto Bosi (2)
1. Laboratory of Pharmacoeconomics, c/o Area Vasta Centro, Regional Health System, Florence, Italy
2. Chair of Haematology, University of Florence, Florence, Italy
文摘
Bortezomib, thalidomide and lenalidomide can be aimed at treating patients with newly diagnosed multiple myeloma (both eligible and ineligible for transplantation) as well as those with relapsed or refractory disease. This review analysed the available clinical and economic data on these three drugs. Irrespective of which of the three agents is considered, the magnitude of the benefit in newly diagnosed cases (transplanted or non-transplanted) tends to be between 10 and 20 months per patient in terms of progression-free survival or survival; the survival benefit is smaller in relapsed or refractory disease. In addition, a single-institution observational analysis evaluated the outcomes in nearly 3000 consecutive patients examined between 1971 and 2006. The survival in patients diagnosed between 2001 and 2006 was longer than that observed in patients diagnosed between 1994 and 2000. This finding supports the conclusion that novel agents provide a survival improvement compared with traditional therapy. Formal cost-effectiveness studies on these three agents are still lacking. A MEDLINE search retrieved only four short papers or letters and no fulllength analysis. Hence, the cost effectiveness of these agents needs further investigation, with separate assessments of the different therapeutic settings. In a simplified analysis, we tried to contrast the average cost of treatment for each of the novel agents versus their respective benefit, expressed in quality-adjusted survival. Despite its preliminary nature, our assessment indicates that the cost effectiveness of these three agents is likely to be within commonly accepted pharmacoeconomic thresholds.